Clinical Trial Results:
An Imaging Sub-Study of the Phase 3 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines.
Summary
|
|
EudraCT number |
2008-004578-42 |
Trial protocol |
DK CZ EE |
Global end of trial date |
11 Nov 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 May 2016
|
First version publication date |
15 May 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MK-0822-032
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Merck Sharp & Dohme Corp.
|
||
Sponsor organisation address |
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
|
||
Public contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Scientific contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
11 Nov 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
14 Nov 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
11 Nov 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
This was an Imaging Sub-Study of Protocol MK-0822-018, A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk. Study MK-0822-018 was an event-driven trial to determine the safety and efficacy, especially fracture-risk reduction, of odanacatib in postmenopausal women 65 years and older who have been diagnosed with osteoporosis.
The main objective of this Imaging Sub-Study (MK-0822-032) was to evaluate the effect of treatment with MK-0822 50 mg once weekly on percent change from baseline in trabecular volumetric bone mineral density (vBMD) at the lumbar spine, compared to placebo at Month 24. The percent change was assessed using Quantitative Computed Tomography (QCT). The primary hypothesis was as follows: Compared to placebo, MK-0822 will increase trabecular vBMD at the lumbar spine (assessed by QCT) from baseline at Month 24.
|
||
Protection of trial subjects |
This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
|
||
Background therapy |
Treatment of postmenopausal women with osteoporosis | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Feb 2009
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 103
|
||
Country: Number of subjects enrolled |
South Africa: 61
|
||
Worldwide total number of subjects |
164
|
||
EEA total number of subjects |
103
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
160
|
||
85 years and over |
4
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
This Sub-Study enrolled postmenopausal women with osteoporosis from Study MK-0822-018. Other inclusion and exclusion criteria applied. | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
A total of 164 participants from Study MK-0822-018 were enrolled in Sub-Study MK-0822-032. Of those enrolled, 160 participants received treatment and were included in the All-Patients-Treated population. | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Odanacatib 50 mg once weekly | |||||||||||||||||||||||||||
Arm description |
Participants received 50 mg of blinded odanacatib once weekly over the course of Study MK-0822-018 and the first Extension (5 years total). Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Odanacatib
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
MK-0822
|
|||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
50 mg of odanacatib once weekly over the course of the Base study and first Extension
|
|||||||||||||||||||||||||||
Arm title
|
Placebo once weekly | |||||||||||||||||||||||||||
Arm description |
Participants received placebo to odanacatib 50 mg weekly over the course of Study MK-0822-018 and the first Extension. Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. | |||||||||||||||||||||||||||
Arm type |
Placebo | |||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
50 mg placebo tablet to odanacatib once weekly over the course of the Base study and first Extension
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Odanacatib 50 mg once weekly
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received 50 mg of blinded odanacatib once weekly over the course of Study MK-0822-018 and the first Extension (5 years total). Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo once weekly
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo to odanacatib 50 mg weekly over the course of Study MK-0822-018 and the first Extension. Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Odanacatib 50 mg once weekly
|
||
Reporting group description |
Participants received 50 mg of blinded odanacatib once weekly over the course of Study MK-0822-018 and the first Extension (5 years total). Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. | ||
Reporting group title |
Placebo once weekly
|
||
Reporting group description |
Participants received placebo to odanacatib 50 mg weekly over the course of Study MK-0822-018 and the first Extension. Participants also received Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) was approximately 1200 mg. |
|
|||||||||||||
End point title |
Percent Change From Baseline in Spine (L1) Trabecular vBMD at Total Vertebral Body (mg/cm3) at Month 24 | ||||||||||||
End point description |
Trabecular vBMD of the lumbar spine was assessed using QCT at Baseline and at Months 12, 24, and 36. This endpoint was based on the full analysis set (FAS) population, which consisted of all randomized participants who received at least one dose of blinded study treatment, have a baseline measurement andat least one on-treatment measurement available.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to Month 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in Least Squares Means | ||||||||||||
Statistical analysis description |
A longitudinal data analysis (LDA) model that included time points at Months 12, 24, and 36, and also factors for treatment, stratum (prior vertebral fracture [yes/no]) and the interaction of time by treatment, was used.
|
||||||||||||
Comparison groups |
Placebo once weekly v Odanacatib 50 mg once weekly
|
||||||||||||
Number of subjects included in analysis |
94
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
LDA model | ||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||
Point estimate |
8.92
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
3.9 | ||||||||||||
upper limit |
13.93 |
|
|||||||||||||
End point title |
Percent Change From Baseline in QCT Total Hip Cortical vBMD (mg/cm3) at Month 24 | ||||||||||||
End point description |
Cortical vBMD of the hip was assessed using QCT at Baseline and at Months 12, 24, and 36. This endpoint was based on the full analysis set (FAS) population, which consisted of all randomized participants who received at least one dose of blinded study treatment, have a baseline measurement and at least one on-treatment measurement available.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline to Month 24
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Difference in Least Squares Means | ||||||||||||
Statistical analysis description |
LDA method that included time points at Months 12, 24, and 36 was used for analysis of QCT Total Hip Cortical vBMD.
|
||||||||||||
Comparison groups |
Odanacatib 50 mg once weekly v Placebo once weekly
|
||||||||||||
Number of subjects included in analysis |
106
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.001 | ||||||||||||
Method |
LDA model | ||||||||||||
Parameter type |
Difference in LS Means | ||||||||||||
Point estimate |
2.76
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
1.43 | ||||||||||||
upper limit |
4.1 |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
With the exception of the qualitative assessment of transilial bone biopsies, there were no safety assessments planned in the context of Sub-Study MK-0822-032. Participant safety assessments will be contained within Study MK-0822-018.
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
Not applicable | ||
Dictionary version |
N/A
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: With the exception of the qualitative assessment of transilial bone biopsies, there were no safety assessments planned in the context of Sub-Study MK-0822-032. Participant safety assessments will be contained within Study MK-0822-018. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
30 Jun 2009 |
Amendment 1: The primary reasons for this amendment were as follows: new information based on Denmark MSD site allocation of participants for Protocol 018; incorporated suggestions and requirements from regulatory agencies and ethics review committee during the protocol review and approval process for the "Lead Cohort"; and clarified protocol based on questions received from sites. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |